Mipi Posts -- BloggingStocks

mipi posts

Analyst initiations: FSLR, JASO, ALU, NOK and ERIC

MOST NOTEWORTHY: First Solar, JA Solar, Alcatel-Lucent, Nokia and Ericsson were today's noteworthy initiations:

First Solar (NASDAQ: FSLR) and JA Solar Holdings (NASDAQ: JASO) were initiated with Buy ratings and targets of $160 and $61 at Collins Stewart. Collins Stewart sees room for margin expansion and is positive on First Solar after channel checks; the firm expects JA Solar to expand capacity given its long-term supply agreements with four wafer suppliers.
Merrill Lynch started shares of Alcatel-Lucent (NYSE: ALU) with a Sell rating, citing a lack of revenue growth prospects.
The firm also started shares of Nokia Corporation (NYSE: NOK) with a Buy rating, as they believe the company's share gains and margin expansion will continue.
Merrill also resumed coverage of Ericsson (NASDAQ: ERIC) with a Neutral rating, expecting high single digit earnings and share growth, but not enough for a Buy rating.

OTHER INITIATIONS:

Goldman initiated the trucking and railroad sectors with Neutral ratings.
Wachovia initiated Isis Pharmaceuticals (NASDAQ: ISIS), BioMarin and Molecular Insight (NASDAQ: MIPI) with Outperform ratings and Bioenvision (NASDAQ: BIVN), Dendreon Corporation (NASDAQ: DNDN), Arena Pharmaceuticals (NASDAQ: ARNA) and Neurocrine Biosciences (NASDAQ: NBIX) with Market Perform ratings.

MOST NOTEWORTHY: Time Warner Cable (TWC) and Molecular Insight Pharmaceuticals (MIPI) were today's more notable initiations:

Time Warner Cable (NYSE: TWC) was initiated at Bernstein with an Outperform rating and $46 target, citing a compelling diversification alternative for cable/CMCS investors. Goldman started Time Warner Cable with a Neutral rating and $44 target.

Molecular Insight Pharmaceuticals Inc (NASDAQ: MIPI) was initiated at RBC with an Outperform rating and $18 target. RBC said Molecular Insight is a leader in developing and commercializing superior radiopharmaceuticals for the treatment and management of life-threatening diseases. Jefferies initiated shares of Molecular Insight with a Buy rating and $20 target, saying Zemiva has blockbuster potential.

OTHER INITIATIONS:

Pacific Growth initiated Ormat Technologies, Inc (NYSE: ORA) with a Buy rating.

Analyst summaries provided by TheFlyOnTheWall.com (subscription required).

#	Blogger	Posts
1	Joseph Lazzaro	114
2	Tom Johansmeyer	107
3	Steven Mallas	51
4	Connie Madon	48
5	Tom Taulli	47
6	Steven Halpern	37
7	Trey Thoelcke	36
8	Mark Fightmaster	35
9	Paul Foster	24
10	Brian White	24
11	Zac Bissonnette	23
12	Brent Archer	22
13	Jon Ogg	22
14	Melly Alazraki	21
15	Jim Cramer	21
16	Eric Buscemi	17
17	Michael Fowlkes	15
18	Michael Shulman	13
19	Sam Collins	11
20	Elizabeth Harrow	11

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.